Hemab Therapeutics Holdings, Inc. (COAG)
Health Care · Rare bleeding disorder therapeutics / clinical-stage biotechnology · Nasdaq
A clinical-stage biotech reimagining treatment of rare blood coagulation disorders with bispecific and monovalent antibodies entering Phase 2–3 trials.
What Hemab Therapeutics Holdings, Inc. does
Hemab Therapeutics is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, including Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease. The company is building a franchise of investigational therapeutics spanning Phase 2 clinical development through discovery research, with multiple value-driving clinical data events anticipated in 2026 and beyond. The company has no approved products and has not generated revenue from product sales.
Themes: ["Blood coagulation disorders","Rare bleeding diseases","Therapeutic antibodies","Bispecific antibodies","Clinical-stage development"]
Fundamentals
- Price$38.03 as of 2026-07-10 close
- Market cap$1.8B as of 2026-07-12
- 1-year return+11.9% as of 2026-07-10 close
- ROE-34.8% as of 2026-07-12
- Debt / equity0.00 as of 2026-07-12
- Beta-1.64 as of 2026-07-12
Key risks (from latest filing)
["Clinical development risk: The company is in early-stage clinical development with multiple products in Phase 1/2 and Phase 2 trials; success is uncertain and regulatory approval is not guaranteed.","Financing risk: The company has incurred significant operating losses ($204.5 million accumulated deficit as of March 31, 2026) and expects to continue incurring substantial losses; continued funding will be required to advance clinical programs.","Manufacturing and commercialization risk: The company has no approved products and must establish manufacturing processes and build sales, marketing, and distribution infrastructure if any candidates receive regulatory approval."]
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.